drugset / Trial / NCT04788797

AN-PEP on Gluten Exposure in Celiacs

NCT04788797 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The AN-PEP, an Aspergillus niger derived endopeptidase, has been developed aiming to produce a complete luminal detoxification of gluten. If AN-PEP is able to produce a complete luminal digestion of gluten in the context of the real life of celiac disease (CeD) patients is unknown. Hypothetically, AN-PEP effect could be detected by the reduction in the excretion of GIP in stool and urine. The objective of this study is to establish the effect of the daily administration of AN-PEP compared to placebo on GIP excretion in an interventional, prospective, randomized, comparative, double-blind study in conditions mimicking the real-life of CeD treated patients. The study consists in a four-week GFD stabilization period followed by a four-week study period with patients randomized to receive active AN-PEP or placebo in a blindly manner.

Timeline

Start
2021-03-17
Primary completion
2022-07-30
Completion
2022-07-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prolyl Endopeptidase Protein / enzyme biologic 2 unknown —

Indications